全球抗體藥物偶聯物(ADC)合同製造市場：按開發階段、運營規模、組件製造、目標適應症、有效負載類型、接頭類型、抗體衍生類型、抗體同種型和區域 2022-2035

本報告研究和分析全球抗體藥物偶聯物 (ADC) 合同製造市場，提供市場格局、細分分析、區域分析、公司概況等。

內容

第一章前言

第 2 章執行摘要

第三章介紹

第 4 章 ADC 合同製造服務提供商：市場格局

• 章節概述
• ADC 合同製造服務提供商：整體市場格局
• 抗體合同製造商名單
• HPAPI/Cytotoxic Payload 合同製造服務提供商列表
• 生物製劑灌裝/整理服務提供商名單

第五章公司簡介

• 章節概述
• MabPlex
• 艾伯維合同製造
• 龍沙
• Catalent 製藥解決方案
• 古德溫生物科技
• Piramal 製藥解決方案
• 密理博西格瑪
• 阿布澤娜
• CARBOGEN AMCIS
• 藥明生物
• Cerbios-Pharma
• 福爾摩沙實驗室
• 創意生物實驗室
• 諾華賽
• Sterling 製藥解決方案

第六章企業競爭力分析

• 章節概述
• 調查方法及主要參數
• ADC 代工製造服務商：公司競爭力分析

第 7 章 ADC 合同製造服務提供商：近□□期擴張

• 章節概述
• ADC 合同製造服務提供商：近□□期擴張

第 8 章 ADC 合同製造服務提供商：合作夥伴和聯盟

• 章節概述
• 合作模式
• ADC 合同製造服務提供商：合作夥伴和聯盟列表

第 9 章。做出與購買的決定

• 章節概述
• 先決條件和關鍵參數
• 結論

第 10 章價值鏈分析

• 章節概述
• ADC 開發價值鏈
• 價值鏈中的成本分配

第 11 章 ADC 製造：產能分析

• 章節概述
• 主要假設和研究方法
• ADC 製造：全球裝機容量

第 12 章 ADC 療法：市場概述

• 章節概述
• ADC 治療列表
• 抗體藥物偶聯物 (ADC)：治療藥物開發商名單

第13章新型ADC偶聯技術平台

• 章節概述
• 第一代 ADC 技術
• 第二代 ADC 技術
• 第三代 ADC 技術
• 其他新的 ADC 技術
• 進化分析

第 14 章臨床試驗分析

• 章節概述
• 範圍和研究方法
• ADC 治療：臨床試驗分析
• ADC 治療：按抗體同種型和區域分析
• ADC 處理：按負載類型和區域分析
• ADC 處理：按連接器類型和區域分析

第十五章潛在合作夥伴分析

• 章節概述
• 範圍和研究方法
• ADC 療法開發商的重要潛在戰略合作夥伴

第 16 章 ADC 處理：需求分析

• 章節概述
• 主要假設和研究方法
• ADC 處理：年需求總量
• ADC 處理：供需分析

第十七章區域生產力評價分析

• 章節概述
• 先決條件和關鍵參數
• 北美地區產能評估
• 歐洲區域產能評估
• 亞太地區區域產能評估
• 結論

第 18 章吸引力/競爭力矩陣

• 章節概述
• 吸引力/競爭力矩陣：概覽
• 分析法
• 吸引力/競爭力矩陣：北美的 ADC 合同製造情景
• 吸引力/競爭力矩陣：歐洲的 ADC 合同製造情景
• 吸引力/競爭力矩陣：亞太地區的 ADC 合同製造情景

第 19 章市場規模和機會分析

• 章節概述
• 輸入數據和關鍵假設
• 預測方法
• 全球 ADC 治療市場（2022-2035 年）
• 全球 ADC 合同製造市場（2022-2035 年）
• 商業產品的 ADC 合同製造市場（2022-2035 年）
• 臨床產品的 ADC 合同製造市場（2022-2035 年）

第 20 章 SWOT 分析

第 21 章結論

第22章採訪記錄

• 章節概述
• Chapter Overview
• BSP Pharmaceuticals
• Oxford BioTherapeutics
• Abzena
• Syndivia
• Cerbios-Pharma
• NBE-Therapeutics
• Eisai
• Synaffix
• Pierre Fabre
• Goodwin Biotechnology
• Cerbios-Pharma
• Catalent Pharma Solutions
• Lonza
• Piramal Pharma Solutions
• Ajinomoto Bio-Pharma Services
• Interview Transcript: Anonymous (Director, Business Development, Leading CMO)
• Interview Transcript: Anonymous (Chief Executive Officer, Leading CMO)

第 23 章。附錄 I：數據表

第 24 章附錄 II：公司和組織列表

INTRODUCTION

In the past two decades, antibody therapeutics have become a key component of the treatment regimens against a range of diseases, specifically cancer. Representing one of the rapidly growing segments of the pharmaceutical industry, a number of technological advancements have been reported in this sector. In this context, a number of researchers are evaluating the potential of antibody drug conjugates (ADCs) for the treatment of a myriad of disease indications. In addition to enabling better efficacy as compared to antibody therapeutics, ADCs exhibit higher stability, reduced toxicity, improved tumor selectivity, increased drug tolerance and less systemic exposure. , It is worth highlighting that, in the last few years, more than 10 ADCs have received the FDA approval. Further, a number of ADCs are being evaluated across 700+ clinical trials for the treatment of a wide array of disorders. To support the ongoing pace of research in this domain, a total of USD 14.8 billion (since 2014) has been invested in this domain by several private / strategic investors and government organizations, indicating the therapeutic potential and growing appeal of this unique class of targeted medicines. However, the production of this therapeutics is associated with several challenges, including generation of antibody aggregates, drug / linker side reactions, containment of highly toxic drug compounds, and lot-to-lot variation in drug-antibody ratio (DAR). Moreover, the manufacturing process often requires the use of cutting-edge linker technologies, which are expensive to acquire.

In order to mitigate the abovementioned challenges associated with ADC manufacturing, around 70-80% players engaged in this domain prefer to outsource their operations to contract manufacturing organizations (CMOs) having the required expertise and experience, in order to leverage their capabilities and yield cost savings opportunities. Currently, the ADC contract manufacturing market landscape is highly fragmented, featuring a mix of start-ups, mid-sized firms and well-established players. Moreover, stakeholders claim to offer a range of services, across different scales of operations; over 35% of such companies have established their facilities across different geographies. Owing to the fact that a number of ADC developers are outsourcing various aspects of their business processes, CMOs engaged in this domain have undertaken several expansion initiatives to become one-stop-shops to cater to the diverse needs of ADC developers. Moreover, given the projected increase in demand for ADCs, the associated contract manufacturing market is anticipated to witness substantial growth in the coming years.

SCOPE OF THE REPORT

The "ADC Contract Manufacturing Market (5th Edition) by Phase of Development (Phase I, Phase II and Phase III), Scale of Operation (Clinical and Commercial), Type of Component Manufacturing (Antibody Manufacturing, HPAPI / Cytotoxic Payload, Linker and Conjugation Manufacturing, and Fill / Finish), Target Indications (Solid Tumors, Hematological Malignancies and Others), Type of Payload (Maytansinoid, Auristatin, Camptothecin, PBD and Others), Type of Linker (SMCC, VC, Malemide, Peptide Linker and Others), Type of Antibody Origin (Humanized, Chimeric, Murine, Human and Others), Antibody Isotype (IgG1and Others) and Geography (North America, Europe, Asia-Pacific and Rest of the World), 2022-2035" report features an extensive study of the current market landscape and the likely future potential associated with the ADC contract manufacturing market, over the next decade. The study includes an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain. Amongst other elements, the report features:

• A detailed overview of the overall market landscape of players engaged in the contract manufacturing of ADCs, based on several relevant parameters, such as company size, year of establishment, location of headquarters, type of service(s) offered (antibody manufacturing, HPAPI and payload synthesis, linker manufacturing, conjugation and fill-finish), other ADC service(s) offered (proof-of-concept studies / process development and scale-up / analytical development), scale of operation (preclinical, clinical and commercial) and location of manufacturing facilities. In addition, it provides details on the antibody contract manufacturers, HPAPI / cytotoxic payload contract manufacturers and biologics fill / finish service providers engaged in this domain.

• A detailed competitiveness analysis of ADC contract manufacturers, based on manufacturing strength (on the basis of scale of operation and number of ADC manufacturing facilities), service strength (based on the number of ADC services offered, number of additional services offered and location of ADC manufacturing facilities), supplier strength (in terms of employee count and years of experience in this field).

• Elaborate profiles of ADC contract manufacturers (shortlisted on the basis of competitiveness analysis). Each profile provides a brief overview of the company, its financial information, along with details on its ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.

• A detailed analysis of the various expansion initiatives undertaken by service providers engaged in this domain, during the period 2012-2022, along with information on several relevant parameters, such as year of expansion, type of expansion (capacity expansion and new facility), type of service(s) offered (manufacturing services, analytical / development services and fill / finish services), location of expanded facility, scale of operation (preclinical, clinical and commercial) and most active players (in terms of number of instances).

• An analysis of the recent partnerships inked between various players engaged in this domain. Additionally, it includes a brief description of the various types of partnership models (manufacturing agreements, product development agreements, research agreements, service alliance, acquisitions, product development and manufacturing agreements, licensing agreements, and others) that have been adopted by stakeholders engaged in this domain.

• A qualitative analysis highlighting the various factors that need to be taken into consideration by ADC developers, while deciding whether to manufacture their respective products in-house or outsource the manufacturing to a contract service provider.

• A detailed discussion on various steps (antibody manufacturing, payload manufacturing, linker manufacturing, conjugation and fill / finish) involved in the manufacturing of ADCs, along with information on the cost requirements across each stages.

• An estimate of the overall ADC manufacturing / bioconjugation capacity (in kilograms) of contract manufacturers of contract manufacturers based on information provided by various stakeholders in the public domain. The analysis highlights the distribution of global capacity by company size (small, mid-sized and large), key geographical regions (North America, Europe and Asia-Pacific) and key players (in terms of highest bioconjugation capacity).

• A detailed overview of the ADCs that are either approved or under development (clinical and preclinical), along with information on their current phase of development (marketed, clinical and preclinical / discovery stage), target indication(s), target antigen, antibody origin, antibody isotype, type of payload and type of linker.

• A review of the evolution of ADC conjugation technologies, highlighting the various types of approaches that have been adopted in the past, and the different generations of linkers. It also highlights the competition between contemporary technology platforms.

• An analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as number of trials registered, trial phase, trial status, target indication, type of sponsor / collaborator and number of patients enrolled.

• An informed estimate of the annual demand for ADC products (in kilograms), taking into account commercial, as well as clinical scale requirements, based on relevant parameters, such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.

• An in-depth analysis of over 80 ADC based therapy developers that are likely to partner with contract service providers engaged in this domain, based on several relevant parameters, such as developer strength (on the basis of company size and its experience), pipeline strength and maturity (on the basis of number of drugs in pipeline, their stage of development and type of target indication) and manufacturing capabilities.

• A detailed regional capability assessment framework, which compares the key geographies, based on a number of parameters, such as the number of ADC contract manufacturers, number of ADC manufacturing facilities, number of facility expansions, installed ADC capacity, number of registered clinical trials and demand for ADCs in that particular geographical region.

• A proprietary 2×2 representation, highlighting the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.

• A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall ADC contract manufacturing market.

One of the key objectives of the report was to estimate the current opportunity and future size of the ADC contract manufacturing market. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, over the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] Phase of Development (Phase I, Phase II and Phase III), [B] Scale of Operation (Clinical and Commercial) [C] Type of Component Manufacturing (Antibody Manufacturing, HPAPI / Cytotoxic Payload, Linker and Conjugation Manufacturing, and Fill / Finish), [D] Target Indications (Solid Tumors, Hematological Malignancies and Others), [E] Type of Payload (Maytansinoid, Auristatin, Camptothecin, PBD and Others), [F] Type of Linker (SMCC, VC, Malemide, Peptide Linker and Others), [G] Type of Antibody Origin (Humanized, Chimeric, Murine, Human and Others), [H] Type of Antibody Isotype (IgG1and Others) and [I] Geography (North America, Europe, Asia-Pacific and Rest of World). In order to account for future uncertainties and add robustness to our forecast model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market's revolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we have conducted interviews with various experts in this domain (academia, industry, medical practice and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

• Annual reports
• Investor presentations
• SEC filings
• Industry databases
• News releases from company websites
• Government policy documents
• Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

The opinions and insights presented in the report were also influenced by discussions held with key stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

• Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals)

• Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics)

• John Burt (ex-Chief Executive Officer, Abzena)

• Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)

• Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)

• Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)

• Takashi Owa (Chief Innovation Officer, Eisai) and Toshimitsu Uenaka (Executive Director, Eisai)

• Anthony DeBoer (Director, Business Development, Synaffix)

• Christian Bailly (ex-Director of CDMO, Pierre Fabre)

• Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (ex-Group Product Manager, Catalent Pharma Solutions)

• David Cunningham (Director Corporate Development, Goodwin Biotechnology)

• Laurent Ducry (ex-Head of Bioconjugates Commercial Development, Lonza)

• Mark Wright (ex-Site Head, Piramal Pharma Solutions)

• Zhala Tawfiq (Associate Scientist, Ajinomoto Bio-Pharma Services)

• Anonymous (Director, Business Development, Leading CMO)

• Anonymous (Chief Executive Officer, Leading CMO)

KEY QUESTIONS ANSWERED

• Who are the key players engaged in providing ADC contract manufacturing services?

• Which regions represent the current contract hub for ADC manufacturing?

• What percentage of ADC manufacturing operations are outsourced?

• In which regions is the expansion activity of ADC contract manufacturers primarily centered?

• What kind of partnership models are commonly adopted by stakeholders in this industry?

• What is the industry attractiveness and competitive strength in the ADC contract manufacturing domain?

• What factors should be taken into consideration while deciding whether the manufacturing operations for ADCs should be kept in-house or outsourced?

• Which therapy developers are likely to partner with ADC contract manufacturers?

• What is the overall cost distribution across various steps of the ADC manufacturing process?

• What is overall ADC manufacturing / bioconjugation capacity (in kilograms) of contract manufacturers?

• How many ADCs are under development and approved?

• Which geographies are most active in conducting ADC clinical trials?

• What is the current, global demand for ADC products?

• How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES

• Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the ADC contract manufacturing market and its likely evolution in the mid to long term.

• Chapter 3 provides a general introduction to ADCs and the manufacturing requirements of such therapeutic products. It includes a detailed discussion on the structure of an ADC and its various components, along with information on the key manufacturing steps involved. The chapter also provides an overview of the growing trend of contract manufacturing, along with the challenges associated with supply chain and the growing demand for one-stop-shops. Further, it features a discussion on the various parameters that a sponsor company needs to consider while selecting a contract manufacturing partner.

• Chapter 4 provides a detailed overview of the overall market landscape of players engaged in the contract manufacturing of ADCs, based on several relevant parameters, such as company size, year of establishment, location of headquarters, type of service(s) offered (antibody manufacturing, HPAPI and payload synthesis, linker manufacturing, conjugation and fill-finish), other ADC service(s) offered (proof-of-concept studies / process development and scale-up / analytical development), scale of operation (preclinical, clinical and commercial) and location of manufacturing facilities. In addition, it provides details on the antibody contract manufacturers, HPAPI / cytotoxic payload contract manufacturers and biologics fill / finish service providers engaged in this domain.

• Chapter 5 features a detailed competitiveness analysis of ADC contract manufacturers, based on manufacturing strength (on the basis of scale of operation and number of ADC manufacturing facilities), service strength (based on the number of ADC services offered, number of additional services offered and location of ADC manufacturing facilities), supplier strength (in terms of employee count and years of experience in this field).

• Chapter 6 Elaborate profiles of ADC contract manufacturers (shortlisted on the basis of competitiveness analysis). Each profile provides a brief overview of the company, its financial information, along with details on its ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.

• Chapter 7 provides a detailed analysis of the various expansion initiatives undertaken by service providers engaged in this domain, during the period 2012-2022, along with information on several relevant parameters, such as year of expansion, type of expansion (capacity expansion and new facility), type of service(s) offered (manufacturing services, analytical / development services and fill / finish services), location of expanded facility, scale of operation (preclinical, clinical and commercial) and most active players (in terms of number of instances).

• Chapter 8 presents an analysis of the recent partnerships inked between various players engaged in this domain. Additionally, it includes a brief description of the various types of partnership models (manufacturing agreements, product development agreements, research agreements, service alliance, acquisitions, product development and manufacturing agreements, licensing agreements, and others) that have been adopted by stakeholders engaged in this domain.

• Chapter 9 presents a qualitative analysis highlighting the various factors that need to be taken into consideration by ADC developers, while deciding whether to manufacture their respective products in-house or outsource the manufacturing to a contract service provider.

• Chapter 10 presents a detailed discussion on various steps (antibody manufacturing, payload manufacturing, linker manufacturing, conjugation and fill / finish) involved in the manufacturing of ADCs, along with information on the cost requirements across each stages.

• Chapter 11 features an estimate of the overall ADC manufacturing / bioconjugation capacity (in kilograms) of contract manufacturers based on information provided by various industry stakeholders in the public domain. It also features the distribution of global capacity on the basis of company size (small, mid-sized and large), key geographical regions (North America, Europe and Asia-Pacific) and key players (in terms of highest bioconjugation capacity).

• Chapter 12 provides an overview of the ADCs that are either approved or under development (clinical and preclinical), along with information on their current phase of development (marketed, clinical and preclinical / discovery stage), target indication(s), target antigen, antibody origin, antibody isotype, type of payload and type of linker.

• Chapter 13 features a review of the evolution of ADC conjugation technologies, highlighting the various types of approaches that have been adopted in the past, and the different generations of linkers. It also highlights the competition between contemporary technology platforms.

• Chapter 14 features an analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as number of trials registered, trial phase, trial status, target indication, type of sponsor / collaborator and number of patients enrolled.

• Chapter 15 features an in-depth analysis of over 80 ADC based therapy developers that are likely to partner with contract service providers engaged in this domain, based on several relevant parameters, such as developer strength (on the basis of company size and its experience), pipeline strength and maturity (on the basis of number of drugs in pipeline, their stage of development and type of target indication) and manufacturing capabilities.

• Chapter 16 provides an informed estimate of the annual demand for ADC products (in kilograms), taking into account commercial, as well as clinical scale requirements, based on relevant parameters, such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.

• Chapter 17 provides a detailed regional capability assessment framework, which compares the key geographies, based on a number of parameters, such as the number of ADC contract manufacturers, number of ADC manufacturing facilities, number of facility expansions, installed ADC capacity, number of registered clinical trials and demand for ADCs in that particular geographical region.

• Chapter 18 features a proprietary 2×2 representation, highlighting the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.

• Chapter 19 presents a comprehensive market forecast analysis, highlighting the likely growth of the contract manufacturing market of ADCs, till 2035. The chapter provides likely distribution of the projected future opportunity based on phase of development (phase I, phase II and phase III), scale of operation (clinical and commercial), type of component manufacturing (antibody manufacturing, HPAPI / cytotoxic payload, linker and conjugation manufacturing, and fill / finish), target indications (solid tumors, hematological malignancies and others), type of payload (maytansinoid, auristatin, camptothecin, PBD and others), type of linker (SMCC, VC, malemide, peptide linker and others), type of antibody origin (humanized, chimeric, murine, human and others), type of antibody isotype (IgG1 and others) and geography (North America, Europe, Asia-Pacific, and Rest of the World).

• Chapter 20 presents a discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall ADC contract manufacturing market.

• Chapter 21 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals), Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics), John Burt (ex-Chief Executive Officer, Abzena), Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia), Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma), Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics), Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai), Anthony DeBoer (Director, Business Development, Synaffix), Christian Bailly (ex-Director of CDMO, Pierre Fabre), David Cunningham (Director Corporate Development, Goodwin Biotechnology), Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (ex-Group Product Manager, Catalent Pharma Solutions), Laurent Ducry (ex-Head of Bioconjugates Commercial Development, Lonza), Mark Wright (ex-Site Head, Piramal Pharma Solutions), Zhala Tawfiq (Associate Scientist, Ajinomoto Bio-Pharma Services), Anonymous (Director, Business Development, Leading CMO) and Anonymous (Chief Executive Officer, Leading CMO).

• Chapter 22 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the ADC contract manufacturing market.

• Chapter 23 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

• Chapter 24 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
• 1.3. Key Questions Answered
• 1.4 Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Key Components of Antibody Drug Conjugates (ADCs)
  • 3.2.1. Antibody
  • 3.2.2. Cytotoxin
  • 3.2.3. Linker
• 3.3. ADC Manufacturing
  • 3.3.1. Key Steps
  • 3.3.2. Technical Challenges
  • 3.3.3. Need for Outsourcing
• 3.4. Challenges Associated with Supply Chain and Method Transfer
  • 3.4.1. Growing Demand for One-Stop-Shops and Integrated Service Providers
• 3.5. Key Considerations While Selecting a CMO Partner
• 3.6. Future Perspective

4. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. ADC Contract Manufacturing Service Providers: Overall Market Landscape
  • 4.2.1. Analysis by Year of Establishment
  • 4.2.2. Analysis By Company Size
  • 4.2.3. Analysis by Location of Headquarters
  • 4.2.4. Analysis by Service(s) Offered
  • 4.2.5. Analysis by Other ADC Service(s) Offered
  • 4.2.6. Analysis by Scale of Operation
  • 4.2.7. Analysis by Location of Dedicated Manufacturing Facility
• 4.3. List of Antibody Contract Manufacturing Service Providers
• 4.4. List of HPAPI / Cytotoxic Payload Contract Manufacturing Service Providers
• 4.5. List of Biologics Fill / Finish Service Providers

5. COMPANY PROFILES

• 5.1. Chapter Overview
• 5.2. MabPlex
  • 5.2.1. Company Overview
  • 5.2.2. ADC Offerings
  • 5.2.3. Manufacturing Facilities
  • 5.2.4. Recent Development and Future Outlook
• 5.3. AbbVie Contract Manufacturing
  • 5.3.1. Company Overview
  • 5.3.2. ADC Offerings
  • 5.3.3. Manufacturing Facilities
  • 5.3.4. Recent Development and Future Outlook
• 5.4. Lonza
  • 5.4.1. Company Overview
  • 5.4.2. Financial Information
  • 5.4.3. ADC Offerings
  • 5.4.4. Manufacturing Facilities
  • 5.4.5. Recent Development and Future Outlook
• 5.5. Catalent Pharma Solutions
  • 5.5.1. Company Overview
  • 5.5.2. Financial Information
  • 5.5.3. ADC Offerings
  • 5.5.4. Manufacturing Facilities
  • 5.5.5. Recent Development and Future Outlook
• 5.6. Goodwin Biotechnology
  • 5.6.1. Company Overview
  • 5.6.2. ADC Offerings
  • 5.6.3. Manufacturing Facilities
  • 5.6.4. Recent Development and Future Outlook
• 5.7. Piramal Pharma Solutions
  • 5.7.1. Company Overview
  • 5.7.2. ADC Offerings
  • 5.7.3. Manufacturing Facilities
  • 5.7.4. Recent Development and Future Outlook
• 5.8. Millipore Sigma
  • 5.8.1. Company Overview
  • 5.8.2. ADC Offerings
  • 5.8.3. Manufacturing Facilities
  • 5.8.4. Recent Development and Future Outlook
• 5.9. Abzena
  • 5.9.1. Company Overview
  • 5.9.2. ADC Offerings
  • 5.9.3. Manufacturing Facilities
  • 5.9.4. Recent Development and Future Outlook
• 5.10. CARBOGEN AMCIS
  • 5.10.1. Company Overview
  • 5.10.2. ADC Offerings
  • 5.10.3. Manufacturing Facilities
  • 5.10.4. Recent Development and Future Outlook
• 5.11. WuXi Biologics
  • 5.11.1. Company Overview
  • 5.11.2. Financial Information
  • 5.11.3. ADC Offerings
  • 5.11.4. Manufacturing Facilities
  • 5.11.5. Recent Development and Future Outlook
• 5.12. Cerbios-Pharma
  • 5.12.1. Company Overview
  • 5.12.2. ADC Offerings
  • 5.12.3. Manufacturing Facilities
  • 5.12.4. Recent Development and Future Outlook
• 5.13. Formosa Laboratories
  • 5.13.1. Company Overview
  • 5.13.2. ADC Offerings
  • 5.13.3. Manufacturing Facilities
  • 5.13.4. Recent Development and Future Outlook
• 5.14. Creative Biolabs
  • 5.14.1. Company Overview
  • 5.14.2. ADC Offerings
  • 5.14.3. Manufacturing Facilities
  • 5.14.4. Recent Development and Future Outlook
• 5.15. Novasep
  • 5.15.1. Company Overview
  • 5.15.2. ADC Offerings
  • 5.15.3. Manufacturing Facilities
  • 5.15.4. Recent Development and Future Outlook
• 5.16. Sterling Pharma Solutions
  • 5.16.1. Company Overview
  • 5.16.2. ADC Offerings
  • 5.16.3. Manufacturing Facilities
  • 5.16.4. Recent Development and Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS

• 6.1. Chapter Overview
• 6.2. Methodology and Key Parameters
• 6.3. ADC Contract Manufacturing Service Providers: Company Competitiveness Analysis
  • 6.3.1. ADC Contract Manufacturing Service Providers based in North America
  • 6.3.2. ADC Contract Manufacturing Service Providers based in Europe
  • 6.3.3. ADC Contract Manufacturing Service Providers based in Asia-Pacific

7. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: RECENT EXPANSIONS

• 7.1. Chapter Overview
• 7.2. ADC Contract Manufacturing Service Providers: Recent Expansions
  • 7.2.1. Analysis by Year of Expansion
  • 7.2.2. Analysis by Type of Expansion
  • 7.2.3. Analysis by Type of Service(s) Offered
  • 7.2.4. Analysis by Location of Expanded Facility
  • 7.2.5. Analysis by Scale of Operation
  • 7.2.6. Most Active Players: Analysis by Number of Expansions

8. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: PARTNERSHIPS AND COLLABORATIONS

• 8.1. Chapter Overview
• 8.2. Partnership Models
• 8.3. ADC Contract Manufacturing Service Providers: List of Partnerships and Collaborations
  • 8.3.1. Analysis by Year of Partnership
  • 8.3.2. Analysis by Type of Partnership
  • 8.3.3. Analysis by Type of Service(s) Provided
  • 8.3.4. Analysis by Scale of Operation
  • 8.3.5. Most Active Players: Analysis by Number of Partnerships
  • 8.3.6. Regional Analysis
    • 8.3.6.1. Local and International Agreements
    • 8.3.6.2. Intercontinental and Intracontinental Agreements

9. MAKE VERSUS BUY DECISION MAKING

• 9.1. Chapter Overview
• 9.2. Assumptions and Key Parameters
  • 9.2.1. Scenario 1
  • 9.2.2. Scenario 2
  • 9.2.3. Scenario 3
  • 9.2.4. Scenario 4
• 9.3. Concluding Remarks

10. VALUE CHAIN ANALYSIS

• 10.1. Chapter Overview
• 10.2. ADC Development Value Chain
• 10.3. Cost Distribution Across the Value Chain
  • 10.3.1. Cost Associated with Antibody Manufacturing
  • 10.3.2. Cost Associated with Payload and Linker Manufacturing
  • 10.3.3. Cost Associated with Conjugation
  • 10.3.4. Cost Associated with Fill / Finish

11. ADC MANUFACTURING: CAPACITY ANALYSIS

• 11.1. Chapter Overview
• 11.2. Key Assumptions and Methodology
• 11.3. ADC Manufacturing: Global Installed Capacity
  • 11.3.1. Analysis by Company Size
  • 11.3.2. Analysis by Location of Headquarters
  • 11.3.3. Analysis by Location of Manufacturing Facilities
    • 11.3.3.1 Analysis by Country
    • 11.3.3.2. Analysis by Continent
  • 11.3.4. Analysis by Key Players

12. ADC THERAPEUTICS: MARKET OVERVIEW

• 12.1. Chapter Overview
• 12.2. List of ADC Therapeutics
  • 12.2.1. Analysis by Phase of Development
  • 12.2.2. Analysis by Target Disease Indication
  • 12.2.3. Analysis by Target Antigen
  • 12.2.4. Analysis by Antibody Isotype
  • 12.2.5. Analysis by Type of Linker
  • 12.2.6. Analysis by Payload / Warhead
  • 12.2.7. Analysis by Type of Payload
• 12.3. Antibody Drug Conjugates: List of Therapy Developers
  • 12.3.1. Analysis by Company Size and Location of Headquarters
  • 12.3.2. List of Discontinued Drugs

13. NOVEL ADC CONJUGATION TECHNOLOGY PLATFORMS

• 13.1. Chapter Overview
• 13.2. First Generation ADC Technologies
• 13.3. Second Generation ADC Technologies
  • 13.3.1. Cysteine and Selenocysteine Engineering
  • 13.3.2. Unnatural Amino Acid Engineering
  • 13.3.3. Amino-Terminal Serine Engineering
• 13.4. Third Generation ADC Technologies
  • 13.4.1. Enzyme-Assisted Ligation Approaches
  • 13.4.2. Glycan Remodeling Approaches
  • 13.4.3. Ligation at Fab Nucleotide-Binding Site
  • 13.4.4. Cysteine Rebridging
  • 13.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
• 13.5. Other Emerging ADC Technologies
• 13.6. Evolutionary Analysis

14. CLINICAL TRIALS ANALYSIS

• 14.1. Chapter Overview
• 14.2. Scope and Methodology
• 14.3. ADC Therapeutics: Clinical Trial Analysis
  • 14.3.1. Analysis by Trial Registration Year
  • 14.3.2. Analysis by Trial Phase
  • 14.3.3. Analysis by Trial Status
  • 14.3.4. Analysis by Type of Payload
  • 14.3.5. Analysis by Type of Linker
  • 14.3.6. Analysis by Antibody Isotope
  • 14.3.7. Most Active Players: Analysis by Number of Clinical Trials
  • 14.3.8. Most Active Sponsors: Analysis by Number of Clinical Trials
  • 14.3.9. Analysis by Number of Trials and Geography
  • 14.3.10. Analysis by Number of Trials, Trial Status and Geography
  • 14.3.11. Analysis by Enrolled Patient Population, Trial Status and Geography
• 14.4. ADC Therapeutics: Analysis by Antibody Isotope and Geography
  • 14.4.1. IgG based Molecules
    • 14.4.1.1. Analysis by Phase of Development and Geography
    • 14.4.1.2. Analysis by Trial Status and Geography
    • 14.4.1.3. Analysis by Enrolled Patient Population and Geography
  • 14.4.2. IgG1 based Molecules
    • 14.4.2.1. Analysis by Phase of Development and Geography
    • 14.4.2.2. Analysis by Trial Status and Geography
    • 14.4.2.3. Analysis by Enrolled Patient Population and Geography
  • 14.4.3. IgG4 based Molecules
    • 14.4.3.1. Analysis by Phase of Development and Geography
    • 14.4.3.2. Analysis by Trial Status and Geography
    • 14.4.3.3. Analysis by Enrolled Patient Population and Geography
  • 14.4.4. Other Antibody Isotope based Molecules
    • 14.4.4.1. Analysis by Phase of Development and Geography
    • 14.4.4.2. Analysis by Trial Status and Geography
    • 14.4.4.3. Analysis by Enrolled Patient Population and Geography
• 14.5. ADC Therapeutics: Analysis by Type of Payload and Geography
  • 14.5.1. Auristatin based Molecules
    • 14.5.1.1. Analysis by Phase of Development and Geography
    • 14.5.1.2. Analysis by Trial Status and Geography
    • 14.5.1.3. Analysis by Enrolled Patient Population and Geography
  • 14.5.2. Calicheamicin (Ozogamicin) based Molecules
    • 14.5.2.1. Analysis by Phase of Development and Geography
    • 14.5.2.2. Analysis by Trial Status and Geography
    • 14.5.2.3. Analysis by Enrolled Patient Population and Geography
  • 14.5.3. Maytansine based Molecules
    • 14.5.3.1. Analysis by Phase of Development and Geography
    • 14.5.3.2. Analysis by Geography and Trial Status and Geography
    • 14.5.3.3. Analysis by Enrolled Patient Population and Geography
  • 14.5.4. Exatecan based Molecules
    • 14.5.4.1. Analysis by Phase of Development and Geography
    • 14.5.4.2. Analysis by Trial Status and Geography
    • 14.5.4.3. Analysis by Enrolled Patient Population and Geography
  • 14.5.5. Maytansinoid based Molecules
    • 14.5.5.1. Analysis by Phase of Development and Geography
    • 14.5.5.2. Analysis by Geography and Trial Status
    • 14.5.5.3. Analysis by Geography and Enrolled Patient Population
  • 14.5.2. Camptothecin based Molecules
    • 14.5.6.1. Analysis by Phase of Development and Geography
    • 14.5.6.2. Analysis by Trial Status and Geography
    • 14.5.6.3. Analysis by Enrolled Patient Population and Geography
  • 14.5.2. Other Payload based Molecules
    • 14.5.7.1. Analysis by Phase of Development and Geography
    • 14.5.7.2. Analysis by Trial Status and Geography
    • 14.5.7.3. Analysis by Enrolled Patient Population and Geography
• 14.6. ADC Therapeutics: Analysis by Type of Linker and Geography
  • 14.6.1. VC based Molecules
    • 14.6.1.1. Analysis by Phase of Development and Geography
    • 14.6.1.2. Analysis by Trial Status and Geography
    • 14.6.1.3. Analysis by Enrolled Patient Population and Geography
  • 14.6.2. Peptide Linker based Molecules
    • 14.6.2.1. Analysis by Phase of Development and Geography
    • 14.6.2.2. Analysis by Trial Status and Geography
    • 14.6.2.3. Analysis by Enrolled Patient Population and Geography
  • 14.6.3. Mc-Val-Cit-PABC based Molecules
    • 14.6.3.1. Analysis by Phase of Development and Geography
    • 14.6.3.2. Analysis by Trial Status and Geography
    • 14.6.3.3. Analysis by Enrolled Patient Population and Geography
  • 14.6.4. AcBut based Molecules
    • 14.6.4.1. Analysis by Phase of Development and Geography
    • 14.6.4.2. Analysis by Trial Status and Geography
    • 14.6.4.3. Analysis by Enrolled Patient Population and Geography
  • 14.6.5. SMCC based Molecules
    • 14.6.5.1. Analysis by Phase of Development and Geography
    • 14.6.5.2. Analysis by Trial Status and Geography
    • 14.6.5.3. Analysis by Enrolled Patient Population and Geography
  • 14.6.6. SPDB based Molecules
    • 14.6.6.1. Analysis by Phase of Development and Geography
    • 14.6.6.2. Analysis by Trial Status and Geography
    • 14.6.6.3. Analysis by Enrolled Patient Population and Geography
  • 14.6.7. Others Linker based Molecules
    • 14.6.7.1. Analysis by Phase of Development and Geography
    • 14.6.7.2. Analysis by Trial Status and Geography
    • 14.6.7.3. Analysis by Enrolled Patient Population and Geography

15. LIKELY PARTNER ANALYSIS

• 15.1. Chapter Overview
• 15.2. Scope and Methodology
• 15.3. Key Potential Strategic Partners for ADC Therapeutics Developers
  • 15.3.1. Likely Partner Opportunities in North America
  • 15.3.2. Likely Partner Opportunities in Europe
  • 15.3.3. Likely Partner Opportunities in Asia-Pacific

16. ADC THERAPEUTICS: DEMAND ANALYSIS

• 16.1. Chapter Overview
• 16.2. Key Assumptions and Methodology
• 16.3. ADC Therapeutics: Overall Annual Demand
  • 16.3.1. ADC Therapeutics: Annual Commercial Demand
    • 16.3.1.1. Analysis by Type of Cancer
    • 16.3.1.2. Analysis by Antibody Origin
    • 16.3.1.3. Analysis by Antibody Isotype
    • 16.3.1.4. Analysis by Type of Payload
    • 16.3.1.5. Analysis by Type of Linker
    • 16.3.1.6 Analysis by Key Geographical Regions
  • 16.3.2. ADC Therapeutics: Annual Clinical Demand
    • 16.3.2.1. Analysis by Phase of Development
    • 16.3.2.2. Analysis by Type of Cancer
    • 16.3.2.3. Analysis by Antibody Origin
    • 16.3.2.4. Analysis by Antibody Isotype
    • 16.3.2.5. Analysis by Type of Payload
    • 16.3.2.6. Analysis by Type of Linker
    • 16.3.2.7. Analysis by Key Geographical Regions
• 16.4. ADC Therapeutics: Demand and Supply Analysis

17. REGIONAL CAPABILITY ASSESSMENT ANALYSIS

• 17.1. Chapter Overview
• 17.2. Assumptions and Key Parameters
• 17.3. Regional Capability Assessment in North America
• 17.4. Regional Capability Assessment in Europe
• 17.5. Regional Capability Assessment in Asia-Pacific
• 17.6. Concluding Remarks

18. ATTRACTIVENESS COMPETETIVENESS MATRIX

• 18.1. Chapter Overview
• 18.2. AC Matrix: Overview
  • 18.2.1. Strong Business Segment
  • 18.2.2. Average Business Segment
  • 18.2.3. Weak Business Segment
• 18.3. Analytical Methodology
• 18.4. AC Matrix: ADC Contract Manufacturing Scenario in North America
• 18.5. AC Matrix: ADC Contract Manufacturing Scenario in Europe
• 18.6. AC Matrix: ADC Contract Manufacturing Scenario in Asia Pacific

19. MARKET SIZING AND OPPORTUNITY ANALYSIS

• 19.1. Chapter Overview
• 19.2. Input Data and Key Assumptions
• 19.3. Forecast Methodology
• 19.4. Global ADC Therapeutics Market, 2022-2035
• 19.5. Global ADC Contract Manufacturing Market, 2022-2035
  • 19.5.1. ADC Contract Manufacturing Market: Analysis by Type of Component Manufacturing, 2022-2035
  • 19.5.2. ADC Contract Manufacturing Market: Analysis by Phase of Development, 2022-2035
• 19.6. ADC Contract Manufacturing Market for Commercial Products, 2022-2035
  • 19.6.1. ADC Contract Manufacturing Market for Commercial Products, Analysis by Type of Component Manufacturing, 2022-2035
    • 19.6.1.1. ADC Contract Manufacturing Market for Commercial Products, Analysis by Antibody Origin, 2022-2035
    • 19.6.1.2. ADC Contract Manufacturing Market for Commercial Products, Analysis by Antibody Isotype, 2022-2035
    • 19.6.1.3. ADC Contract Manufacturing Market for Commercial Products, Analysis by Type of Payload, 2022-2035
    • 19.6.1.4. ADC Contract Manufacturing Market for Commercial Products, Analysis by Type of Linker, 2022-2035
  • 19.6.2. ADC Contract Manufacturing Market for Commercial Products, Analysis by Type of Cancer, 2022-2035
  • 19.6.3. ADC Contract Manufacturing Market for Commercial Products, Analysis by Key Geographical Regions, 2022-2035
    • 19.6.3.1. ADC Contract Manufacturing Market for Commercial Products in North America, 2022-2035
    • 19.6.3.2. ADC Contract Manufacturing Market for Commercial Products in EU5, 2022-2035
    • 19.6.3.3. ADC Contract Manufacturing Market for Commercial Products in Rest of the World, 2022-2035
• 19.7. ADC Contract Manufacturing Market for Clinical Products, 2022-2035
  • 19.7.1. ADC Contract Manufacturing Market for Clinical Products, Analysis by Type of Component Manufacturing, 2022-2035
    • 19.7.1.1. ADC Contract Manufacturing Market for Clinical Products, Analysis by Antibody Origin, 2022-2035
    • 19.7.1.2. ADC Contract Manufacturing Market for Clinical Products, Analysis by Antibody Isotype, 2022-2035
    • 19.7.1.3. ADC Contract Manufacturing Market for Clinical Products, Analysis by Type of Payload, 2022-2035
    • 19.7.1.4. ADC Contract Manufacturing Market for Clinical Products, Analysis by Type of Linker, 2022-2035
  • 19.7.2. ADC Contract Manufacturing Market for Clinical Products, Analysis by Type of Cancer, 2022-2035
  • 19.7.3. ADC Contract Manufacturing Market for Clinical Products, Analysis by Key Geographical Regions, 2022-2035
    • 19.7.3.1. ADC Contract Manufacturing Market for Clinical Products in North America, 2022-2035
    • 19.7.3.2. ADC Contract Manufacturing Market for Clinical Products in Europe, 2022-2035
    • 19.7.3.3. ADC Contract Manufacturing Market for Clinical Products in Asia-Pacific, 2022-2035
    • 19.7.3.4. ADC Contract Manufacturing Market for Clinical Products in MENA, 2022-2035
    • 19.7.3.5. ADC Contract Manufacturing Market for Clinical Products in Latin America, 2022-2035
    • 19.7.3.6. ADC Contract Manufacturing Market for Clinical Products in Rest of the World, 2022-2035

20. SWOT ANALYSIS

• 20.1. Chapter Overview
• 20.2. Strengths
• 20.3. Weaknesses
• 20.4. Opportunities
• 20.5. Threats
• 20.6. Comparison of SWOT Factors

21. CONCLUDING REMARKS

22. INTERVIEW TRANSCRIPTS

• 22.1. Chapter Overview
• 22.2. BSP Pharmaceuticals
  • 22.2.1. Company Snapshot
  • 22.2.2. Interview Transcript: Aldo Braca (Chief Executive Officer and Giorgio Salciarini, Technical Business Development Manager)
• 22.3. Oxford BioTherapeutics
  • 22.3.1. Company Snapshot
  • 22.3.2. Interview Transcript: Christian Rohlff (Chief Executive Officer & Founder)
• 22.4. Abzena
  • 22.4.1. Company Snapshot
  • 22.4.2. Interview Transcript: ex-John Burt (Chief Executive Officer)
• 22.5. Syndivia
  • 22.5.1. Company Snapshot
  • 22.5.2. Interview Transcript: Sasha Koniev (Chief Executive Officer & Co-Founder)
• 22.6. Cerbios-Pharma
  • 22.6.1. Company Snapshot
  • 22.6.2. Interview Transcript: Denis Angioletti (Chief Commercial Officer)
• 22.7. NBE-Therapeutics
  • 22.7.1. Company Snapshot
  • 22.7.2. Interview Transcript: Wouter Verhoeven (Chief Business Officer)
• 22.8. Eisai
  • 22.8.1. Company Snapshot
  • 22.8.2. Interview Transcript: Toshimitsu Uenaka (Executive Director and Takashi Owa, Chief Innovation Officer)
• 22.9. Synaffix
  • 22.9.1. Company Snapshot
  • 22.9.2. Interview Transcript: Anthony DeBoer (Director, Business Development)
• 22.10. Pierre Fabre
  • 22.10.1. Company Snapshot
  • 22.10.2. Interview Transcript: ex-Christian Bailly (Director of CDMO)
• 22.11. Goodwin Biotechnology
  • 22.11.1. Company Snapshot
  • 22.11.2. Interview Transcript: David Cunningham (Director Corporate Development)
• 22.12. Cerbios-Pharma
  • 22.12.1. Company Snapshot
  • 22.12.2. Interview Transcript: Vitor Sousa (Business Development Manager)
• 22.13. Catalent Pharma Solutions
  • 22.13.1. Company Snapshot
  • 22.13.2. Interview Transcript: Jennifer L. Mitcham (Director, Business Development and Stacy McDonald, ex-Group Product Manager)
• 22.14. Lonza
  • 22.14.1. Company Snapshot
  • 22.14.2. Interview Transcript: Laurent Ducry (ex-Head of Bioconjugates Commercial Development)
• 22.15. Piramal Pharma Solutions
  • 22.15.1. Company Snapshot
  • 22.15.2. Interview Transcript: Mark Wright (ex-Site Head)
• 22.16. Ajinomoto Bio-Pharma Services
  • 22.16.1. Company Snapshot
  • 22.16.2. Interview Transcript: Zhala Tawfiq (Associate General Manager)
• 22.17. Interview Transcript: Anonymous (Director, Business Development, Leading CMO)
• 22.18. Interview Transcript: Anonymous (Chief Executive Officer, Leading CMO)

23. APPENDIX I: TABULATED DATA

24. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF TABLES

• Table 3.1 Common Cytotoxins Used for the Production of ADC Therapeutics
• Table 3.2 Safebridge / OEL bands for HPAPI / Cytotoxic Payloads
• Table 4.1 ADC Contract Manufacturing Service Providers: List of Companies
• Table 4.2 ADC Contract Manufacturing Service Providers: Information on Type of Service(s) Offered
• Table 4.3 ADC Contract Manufacturing Service Providers: Information on Other ADC Service(s) Offered
• Table 4.4 ADC Contract Manufacturing Service Providers: Information on Scale of Operation
• Table 4.5 ADC Contract Manufacturing Service Providers: Information on Location of Dedicated Manufacturing Facilities
• Table 4.6 ADC Contract Manufacturing Service Providers: List of Antibody Manufacturing Service Providers,
• Table 4.7 ADC Contract Manufacturing Service Providers: List of HPAPI and Cytotoxic Payloads Manufacturing Service Providers,
• Table 4.8 ADC Manufacturing Service Providers: List of Biologics Fill / Finish Service Providers
• Table 5.1 MabPlex: Company Overview
• Table 5.2 MabPlex: ADC Related Offerings
• Table 5.3 MabPlex: Information on Manufacturing Facilities
• Table 5.4 MabPlex: Recent Developments and Future Outlook
• Table 5.5 AbbVie Contract Manufacturing: Company Overview
• Table 5.6 AbbVie Contract Manufacturing: ADC Related Offerings
• Table 5.7 AbbVie Contract Manufacturing: Information on Manufacturing Facilities
• Table 5.8 Lonza: Company Overview
• Table 5.9 Lonza: ADC Related Offerings
• Table 5.10 Lonza: Information on Manufacturing Facilities
• Table 5.11 Lonza: Recent Developments and Future Outlook
• Table 5.12 Catalent Pharma Solutions: Company Overview
• Table 5.13 Catalent Pharma Solutions: ADC Related Offerings
• Table 5.14 Catalent Pharma Solutions: Information on Manufacturing Facilities
• Table 5.15 Catalent Pharma Solutions: Recent Developments and Future Outlook
• Table 5.16 Goodwin Biotechnology: Company Overview
• Table 5.17 Goodwin Biotechnology: ADC Related Offerings
• Table 5.18 Goodwin Biotechnology: Information on Manufacturing Facilities
• Table 5.19 Goodwin Biotechnology: Recent Developments and Future Outlook
• Table 5.20 Piramal Pharma Solutions: Company Overview
• Table 5.21 Piramal Pharma Solutions: ADC Related Offerings
• Table 5.22 Piramal Pharma Solutions: Information on Manufacturing Facilities
• Table 5.23 Piramal Pharma Solutions: Recent Developments and Future Outlook
• Table 5.24 Millipore Sigma: Company Overview
• Table 5.25 Millipore Sigma: ADC Related Offerings
• Table 5.26 Millipore Sigma: Information on Manufacturing Facilities
• Table 5.27 Millipore Sigma: Recent Developments and Future Outlook
• Table 5.28 Abzena: ADC Related Offerings
• Table 5.29 Abzena: Information on Manufacturing Facilities
• Table 5.30 Abzena: Recent Developments and Future Outlook
• Table 5.31 CARBOGEN AMCIS: Company Overview
• Table 5.32 CARBOGEN AMCIS: Information on Manufacturing Facilities
• Table 5.33 CARBOGEN AMCIS: Recent Developments and Future Outlook
• Table 5.34 WuXi Biologics: Company Overview
• Table 5.35 WuXi Biologics: ADC Related Offerings
• Table 5.36 WuXi Biologics: Information on Manufacturing Facilities
• Table 5.37 WuXi Biologics: Recent Developments and Future Outlook
• Table 5.38 Cerbios-Pharma: Company Overview
• Table 5.39 Cerbios-Pharma: ADC Related Offerings
• Table 5.40 Cerbios-Pharma: Information on Manufacturing Facilities
• Table 5.41 Cerbios-Pharma: Recent Developments and Future Outlook
• Table 5.42 Formosa Laboratories: Company Overview
• Table 5.43 Formosa Laboratories: ADC Related Offerings
• Table 5.44 Formosa Laboratories: Information on Manufacturing Facilities
• Table 5.45 Formosa Laboratories: Recent Developments and Future Outlook
• Table 5.46 Creative Biolabs: Company Overview
• Table 5.47 Creative Biolabs: ADC Related Offerings
• Table 5.48 Creative Biolabs: Information on Manufacturing Facilities
• Table 5.49 Creative Biolabs: Recent Developments and Future Outlook
• Table 5.50 Novasep: Company Overview
• Table 5.51 Novasep: ADC Related Offerings
• Table 5.52 Novasep: Information on Manufacturing Facilities
• Table 5.53 Novasep: Recent Developments and Future Outlook
• Table 5.54 Sterling Pharma Solutions: Company Overview
• Table 5.55 Sterling Pharma Solutions: ADC Related Offerings
• Table 5.56 Sterling Pharma Solutions: Information on Manufacturing Facilities
• Table 5.57 Sterling Pharma Solutions: Recent Developments and Future Outlook
• Table 7.1 ADC Contract Manufacturing Service Providers: Recent Facility Expansions, 2012-2021
• Table 8.1 ADC Contract Manufacturing Service Providers: Partnerships and Collaborations, 2012-2021
• Table 10.1 ADC Component: Information on Cost by Type of Cytotoxin
• Table 10.2 ADC Components: Information on Cost by Type of Linker
• Table 11.1 Installed Global Capacity for ADC Manufacturing: Sample Data Set
• Table 11.2 Installed Global Capacity for ADC Manufacturing: Sample Data Set (Average Capacity)
• Table 11.3 Installed Global Capacity for ADC Manufacturing: Information on Total Capacity based on Company Size
• Table 12.1 ADC Therapeutics: List of ADC Therapeutics
• Table 12.2 ADC Therapeutics: List of Therapy Developers
• Table 12.3 ADC Therapeutics: List of Discontinued Drugs
• Table 13.1 Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
• Table 13.2 Second Generation ADC Technologies: Unnatural Amino Acid Engineering
• Table 13.3 Second Generation ADC Technologies: Amino-terminal Engineered Serine
• Table 13.4 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
• Table 13.5 Third Generation ADC Technologies: Glycan Remodeling Approaches
• Table 13.6 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
• Table 13.7 Third Generation ADC Technologies: Cysteine Rebridging
• Table 13.8 Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
• Table 15.1 Likely Partners for ADC Contract Manufacturers in North America
• Table 15.2 Likely Partners for ADC Contract Manufacturers in Europe
• Table 15.3 Likely Partners for ADC Contract Manufacturers in Asia-Pacific
• Table 16.1 List of Late Stage ADCs
• Table 16.2 ADC Therapeutics: Annual Demand for Outsourcing, 2022-2035 (in kg)
• Table 16.3 ADC Therapeutics: Annual Supply for Outsourcing, 2022-2035 (in kgs)
• Table 17.1 ADC Therapeutics: Development Status of Late Stage Candidates
• Table 17.2 ADC Therapeutics: Outsourcing Activity for Late Stage Candidates
• Table 20.1 ADC Therapeutics: Discontinued Drugs
• Table 22.1 BSP Pharmaceuticals: Key Highlights
• Table 22.2 Oxford BioTherapeutics: Key Highlights
• Table 22.3 Abzena: Key Highlights
• Table 22.4 Syndivia: Key Highlights
• Table 22.5 Cerbios-Pharma: Key Highlights
• Table 22.6 NBE-Therapeutics: Key Highlights
• Table 22.7 Eisai: Key Highlights
• Table 22.8 Synaffix: Key Highlights
• Table 22.9 Pierre Fabre: Key Highlights
• Table 22.10 Goodwin Biotechnology: Key Highlights
• Table 22.11 Catalent Pharma Solutions: Key Highlights
• Table 22.12 Lonza: Key Highlights
• Table 22.13 Piramal Pharma Solutions: Key Highlights
• Table 22.14 Ajinomoto Bio-Pharma Services: Key Highlights
• Table 23.1 ADC Contract Manufacturing Service Providers: Distribution by Year of Establishment
• Table 23.2 ADC Contract Manufacturing Service Providers: Distribution by Company Size
• Table 23.3 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters
• Table 23.4 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters and Company Size
• Table 23.5 ADC Contract Manufacturing Service Providers: Distribution by Type of Service(s) Offered
• Table 23.6 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters and Service(s) Offered
• Table 23.7 ADC Contract Manufacturing Service Providers: Distribution by Other ADC Service(s) Offered
• Table 23.8 ADC Contract Manufacturing Service Providers: Distribution by Scale of Operation
• Table 23.9 ADC Contract Manufacturing Service Providers: Distribution by Type of Service(s) offered and scale of operation
• Table 23.10 ADC Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
• Table 23.11 Lonza: Annual Revenues, 2017-2021 (CHF Billion)
• Table 23.12 Catalent Pharma Solutions: Annual Revenues, 2017-2021 (USD Billion)
• Table 23.13 WuXi Biologics: Annual Revenues, 2017-2021 (RMB Billion)
• Table 23.14 Recent Expansions: Cumulative Year-wise Trend, 2012-2021
• Table 23.15 Recent Expansions: Distribution by Type of Expansion
• Table 23.16 Recent Expansions: Distribution by Type of Service(s) Offered
• Table 23.17 Recent Expansions: Distribution by Year of Expansion and Type of Service(s) Offered
• Table 23.18 Recent Expansions: Distribution by Location of Expanded Facility
• Table 23.19 Recent Expansions: Distribution by Scale of Operation
• Table 23.20 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
• Table 23.21 Most Active Players: Distribution by Number of Expansions
• Table 23.22 Partnerships and Collaborations: Cumulative Year-wise Trend of Partnerships, 2012-2021
• Table 23.23 Partnerships and Collaborations: Distribution by Type of Partnership
• Table 23.24 Partnerships and Collaborations: Distribution by Year and Type of Partnership
• Table 23.25 Partnerships and Collaborations: Distribution by Type of Service(s) Provided
• Table 23.26 Partnerships and Collaborations: Distribution by Scale of Operation
• Table 23.27 Most Active Players: Distribution by Number of Partnerships
• Table 23.28 Partnerships and Collaborations: Local and International Distribution
• Table 23.29 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
• Table 23.30 Overall Installed ADC Manufacturing Capacity: Distribution by Company Size
• Table 23.31 Overall Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
• Table 23.32 Overall Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
• Table 23.33 Overall Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Continent-wise)
• Table 23.34 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
• Table 23.35 ADC Therapeutics: Distribution by Phase of Development
• Table 23.36 ADC Therapeutics: Distribution by Target Disease Indication
• Table 23.37 ADC Therapeutics: Distribution by Target Antigen
• Table 23.38 ADC Therapeutics: Distribution by Antibody Isotype
• Table 23.39 ADC Therapeutics: Distribution by Type of Linker
• Table 23.40 ADC Therapeutics: Distribution by Type of Payload / Warhead
• Table 23.41 ADC Therapeutics: Distribution by Type of Payload
• Table 23.42 Antibody Drug Conjugate Developers: Distribution by Company Size and Location of Headquarters
• Table 23.43 Clinical Trial Analysis: Distribution by Trial Registration Year
• Table 23.44 Clinical Trial Analysis: Distribution by Trial Phase
• Table 23.45 Clinical Trial Analysis: Distribution by Trial Status
• Table 23.46 Clinical Trial Analysis: Distribution by Type of Payload
• Table 23.47 Clinical Trial Analysis: Distribution by Type of Linker
• Table 23.48 Clinical Trial Analysis: Distribution by Antibody Isotype
• Table 23.49 Most Active Players: Distribution by Number of Clinical Trials
• Table 23.50 Most Active Sponsors: Distribution by Number of Clinical Trials
• Table 23.51 Clinical Trial Analysis: Distribution by Number of Trials and Geography
• Table 23.52 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
• Table 23.53 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geography
• Table 23.54 Geographical Clinical Trial Analysis: Distribution by Antibody Isotype and Geography
• Table 23.55 Geographical Clinical Trial Analysis (IgG based Molecules): Distribution by Phase of Development and Geography
• Table 23.56 Geographical Clinical Trial Analysis (IgG based Molecules): Distribution by Trial Status and Geography
• Table 23.57 Geographical Clinical Trial Analysis (IgG based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.58 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Phase of Development and Geography
• Table 23.59 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Trial Status and Geography
• Table 23.60 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.61 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Phase of Development and Geography
• Table 23.62 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Trial Status and Geography
• Table 23.63 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.64 Geographical Clinical Trial Analysis (Other Antibody Isotope based Molecules): Distribution by Phase of Development and Geography
• Table 23.65 Geographical Clinical Trial Analysis (Other Antibody Isotope based Molecules): Distribution by Trial Status and Geography
• Table 23.66 Geographical Clinical Trial Analysis (Other Antibody Isotope based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.67 Geographical Clinical Trial Analysis: Distribution by Type of Payload and Geography
• Table 23.68 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Phase of Development and Geography
• Table 23.69 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Status and Geography
• Table 23.70 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.71 Geographical Clinical Trial Analysis (Calicheamicin (Ozogamicin) based Molecules): Distribution by Phase of Development and Geography
• Table 23.72 Geographical Clinical Trial Analysis (Calicheamicin (Ozogamicin) based Molecules): Distribution by Trial Status and Geography
• Table 23.73 Geographical Clinical Trial Analysis (Calicheamicin (Ozogamicin) based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.74 Geographical Clinical Trial Analysis (Maytansine based Molecules): Distribution by Phase of Development and Geography
• Table 23.75 Geographical Clinical Trial Analysis (Maytansine based Molecules): Distribution by Trial Status and Geography
• Table 23.76 Geographical Clinical Trial Analysis (Maytansine based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.77 Geographical Clinical Trial Analysis (Exatecan based Molecules): Distribution by Phase of Development and Geography
• Table 23.78 Geographical Clinical Trial Analysis (Exatecan based Molecules): Distribution by Trial Status and Geography
• Table 23.79 Geographical Clinical Trial Analysis (Exatecan based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.80 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Phase of Development and Geography
• Table 23.81 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Status and Geography
• Table 23.82 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.83 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Phase of Development and Geography
• Table 23.84 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Trial Status and Geography
• Table 23.85 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.86 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Phase of Development and Geography
• Table 23.87 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Trial Status and Geography
• Table 23.88 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.89 Geographical Clinical Trial Analysis: Distribution by Type of Linker and Geography
• Table 23.90 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Phase of Development and Geography
• Table 23.91 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Status and Geography
• Table 23.92 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.93 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Phase of Development and Geography
• Table 23.94 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Trial Status and Geography
• Table 23.95 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.96 Geographical Clinical Trial Analysis (Mc-Val-Cit-PABC based Molecules): Distribution by Phase of Development and Geography
• Table 23.97 Geographical Clinical Trial Analysis (Mc-Val-Cit-PABC based Molecules): Distribution by Trial Status and Geography
• Table 23.98 Geographical Clinical Trial Analysis (Mc-Val-Cit-PABC based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.99 Geographical Clinical Trial Analysis (AcBut based Molecules): Distribution by Phase of Development and Geography
• Table 23.100 Geographical Clinical Trial Analysis (AcBut based Molecules): Distribution by Trial Status and Geography
• Table 23.101 Geographical Clinical Trial Analysis (AcBut based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.102 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Phase of Development and Geography
• Table 23.103 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Status and Geography
• Table 23.104 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.105 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Phase of Development and Geography
• Table 23.106 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Status and Geography
• Table 23.107 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.108 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Phase of Development and Geography
• Table 23.109 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Trial Status and Geography
• Table 23.110 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Enrolled Patient Population and Geography
• Table 23.111 Global Demand for ADC Therapeutics, 2022-2035 (in kg)
• Table 23.112 Global Demand for ADC Therapeutics: Distribution by Phase of Development, 2022-2035 (in kg)
• Table 23.113 Global Annual Commercial Demand for ADC Therapeutics, 2022-2035 (in kg)
• Table 23.114 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Cancer, 2022-2035 (in kg)
• Table 23.115 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
• Table 23.116 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2022-2035 (in kg)
• Table 23.117 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload Type, 2022-2035 (in kg)
• Table 23.118 Global Commercial Demand for ADC Therapeutics: Distribution by Type fo Linker, 2022-2035 (in kg)
• Table 23.119 Global Commercial Demand for ADC Therapeutics: Distribution by Key Geographical Regions, 2022-2035 (in kg)
• Table 23.120 Global Annual Clinical Demand for ADC Therapeutics, 2022-2035 (in kg)
• Table 23.121 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2022-2035 (in kg)
• Table 23.122 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Cancer, 2022-2035 (in kg)
• Table 23.123 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
• Table 23.124 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2022-2035 (in kg)
• Table 23.125 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2022-2035 (in kg)
• Table 23.126 Global Clinical Demand for ADC Therapeutics: Distribution by Linker Type, 2022-2035 (in kg)
• Table 23.127 Global Clinical Demand for ADC Therapeutics: Distribution by Key Geographical Regions, 2022-2035 (in kg)
• Table 23.128 ADC Therapeutics: Demand and Supply Scenario, 2022-2035
• Table 23.129 Global ADC Therapeutics Market, 2022-2035 (USD Billion)
• Table 23.130 Global ADC Contract Manufacturing Market, 2022-2035
• Table 23.131 ADC Contract Manufacturing Market: Distribution by Type of Component Manufacturing, 2022-2035
• Table 23.132 ADC Contract Manufacturing Market: Distribution by Phase of Development, 2022-2035
• Table 23.133 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Component Manufacturing, 2022-2035
• Table 23.134 ADC Contract Manufacturing Market for Commercial Products: Distribution by Antibody Origin, 2022-2035
• Table 23.135 ADC Contract Manufacturing Market for Commercial Products: Distribution by Antibody Isotype, 2022-2035
• Table 23.136 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Payload, 2022-2035
• Table 23.137 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Linker, 2022-2035
• Table 23.138 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Cancer, 2022-2035
• Table 23.139 ADC Contract Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035
• Table 23.140 ADC Contract Manufacturing Market for Commercial Products in North America, 2022-2035
• Table 23.141 ADC Contract Manufacturing Market for Commercial Products in EU5, 2022-2035
• Table 23.142 ADC Contract Manufacturing Market for Commercial Products in Rest of the World, 2022-2035
• Table 23.143 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Component Manufacturing, 2022-2035
• Table 23.144 ADC Contract Manufacturing Market for Clinical Products: Distribution by Antibody Origin, 2022-2035
• Table 23.145 ADC Contract Manufacturing Market for Clinical Products: Distribution by Antibody Isotype, 2022-2035
• Table 23.146 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Payload, 2022-2035
• Table 23.147 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Linker, 2022-2035
• Table 23.148 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Cancer, 2022-2035
• Table 23.149 ADC Contract Manufacturing Market for Clinical Products: Distribution by Key Geographical Regions, 2022-2035
• Table 23.150 ADC Contract Manufacturing Market for Clinical Products in North America, 2022-2035
• Table 23.151 ADC Contract Manufacturing Market for Clinical Products in Europe, 2022-2035
• Table 23.152 ADC Contract Manufacturing Market for Clinical Products in Asia-Pacific, 2022-2035
• Table 23.153 ADC Contract Manufacturing Market for Clinical Products in MENA, 2022-2035
• Table 23.154 ADC Contract Manufacturing Market for Clinical Products in Latin America, 2022-2035
• Table 23.155 ADC Contract Manufacturing Market for Clinical Products in Rest of the World, 2022-2035

LIST OF FIGURES

• Figure 2.1 Executive Summary: Current Market Landscape of ADC Contract Manufacturing Service Providers
• Figure 2.2 Executive Summary: Expansions
• Figure 2.3 Executive Summary: Partnerships and Collaborations
• Figure 2.4 Executive Summary: Capacity Analysis
• Figure 2.5 Executive Summary: Clinical Trial Analysis
• Figure 2.6 Executive Summary: Demand Analysis
• Figure 2.7 Executive Summary: Market Sizing and Opportunity Analysis
• Figure 3.1 Key Components of an ADC
• Figure 3.2 Manufacturing Steps of an ADC
• Figure 3.3 Key Considerations While Selecting a CMO Partner
• Figure 4.1 ADC Contract Manufacturing Service Providers: Distribution by Year of Establishment
• Figure 4.2 ADC Contract Manufacturing Service Providers: Distribution by Company Size
• Figure 4.3 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters
• Figure 4.4 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters and Company Size
• Figure 4.5 ADC Contract Manufacturing Service Providers: Distribution by Type of Service(s) Offered
• Figure 4.6 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters and Service(s) Offered
• Figure 4.7 ADC Contract Manufacturing Service Providers: Distribution by Other ADC Service(s) Offered
• Figure 4.8 ADC Contract Manufacturing Service Providers: Distribution by Scale of Operation
• Figure 4.9 ADC Contract Manufacturing Service Providers: Distribution by Type of Service(s) offered and scale of operation
• Figure 4.10 ADC Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
• Figure 5.1 Lonza: Annual Revenues, 2017-2021 (CHF Billion)
• Figure 5.2 Catalent Pharma Solutions: Annual Revenues, 2017-2021 (USD Billion)
• Figure 5.3 WuXi Biologics: Annual Revenues, 2017-2021 (RMB Billion)
• Figure 6.1 Company Competitiveness Analysis: ADC Contract Manufacturing Service Providers based in North America
• Figure 6.2 Company Competitiveness Analysis: ADC Contract Manufacturing Service Providers based in Europe
• Figure 6.3 Company Competitiveness Analysis: ADC Contract Manufacturing Service Providers based in Asia-Pacific
• Figure 7.1 Recent Expansions: Cumulative Year-wise Trend, 2013-2022
• Figure 7.2 Recent Expansions: Distribution by Type of Expansion
• Figure 7.3 Recent Expansions: Distribution by Type of Service(s) Offered
• Figure 7.4 Recent Expansions: Distribution by Year of Expansion and Type of Service(s) Offered
• Figure 7.5 Recent Expansions: Distribution by Location of Expanded Facility
• Figure 7.6 Recent Expansions: Distribution by Scale of Operation
• Figure 7.7 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
• Figure 7.8 Most Active Players: Distribution by Number of Expansions
• Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend of Partnerships, 2012-2021
• Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
• Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
• Figure 8.4 Partnerships and Collaborations: Distribution by Type of Service(s) Provided
• Figure 8.5 Partnerships and Collaborations: Distribution by Scale of Operation
• Figure 8.6 Most Active Players: Distribution by Number of Partnerships
• Figure 8.7 Partnerships and Collaborations: Local and International Distribution
• Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
• Figure 9.1 Make versus Buy: Decision Making Framework
• Figure 9.2 Make versus Buy Decision Making: Possible Scenario Descriptions
• Figure 10.1 Value Chain Analysis: ADC Development Overview
• Figure 10.2 Value Chain Analysis: ADC Contract Manufacturing Overview
• Figure 10.3 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing
• Figure 10.4 Value Chain Analysis: Distribution by Cost
• Figure 10.5 Costs Associated with Antibody Manufacturing
• Figure 10.6 Costs Associated with Payload and Linker Manufacturing
• Figure 10.7 Costs Associated with Conjugation
• Figure 10.8 Costs Associated with Fill / Finish
• Figure 11.1 Overall Installed ADC Manufacturing Capacity: Distribution by Company Size
• Figure 11.2 Overall Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
• Figure 11.3 Overall Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
• Figure 11.4 Overall Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Continent-wise)
• Figure 11.5 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
• Figure 12.1 ADC Therapeutics: Distribution by Phase of Development
• Figure 12.2 ADC Therapeutics: Distribution by Target Disease Indication
• Figure 12.3 ADC Therapeutics: Distribution by Target Antigen
• Figure 12.4 ADC Therapeutics: Distribution by Antibody Isotype
• Figure 12.5 ADC Therapeutics: Distribution by Type of Linker
• Figure 12.6 ADC Therapeutics: Distribution by Type of Payload / Warhead
• Figure 12.7 ADC Therapeutics: Distribution by Type of Payload
• Figure 12.8 Antibody Drug Conjugate Developers: Distribution by Company Size and Location of Headquarters
• Figure 13.1 ADC Conjugation Platforms: Technological Evolution
• Figure 13.2 ADC Conjugation Platforms: Technology Landscape
• Figure 14.1 Clinical Trial Analysis: Distribution by Trial Registration Year
• Figure 14.2 Clinical Trial Analysis: Distribution by Trial Phase
• Figure 14.3 Clinical Trial Analysis: Distribution by Trial Status
• Figure 14.4 Clinical Trial Analysis: Distribution by Type of Payload
• Figure 14.5 Clinical Trial Analysis: Distribution by Type of Linker
• Figure 14.6 Clinical Trial Analysis: Distribution by Antibody Isotype
• Figure 14.7 Most Active Players: Distribution by Number of Clinical Trials
• Figure 14.8 Most Active Sponsors: Distribution by Number of Clinical Trials
• Figure 14.9 Clinical Trial Analysis: Distribution by Number of Trials and Geography
• Figure 14.10 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
• Figure 14.11 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geography
• Figure 14.12 Clinical Trial Analysis: Distribution by Antibody Isotype and Geography
• Figure 14.13 Geographical Clinical Trial Analysis (IgG based Molecules): Distribution by Phase of Development
• Figure 14.14 Geographical Clinical Trial Analysis (IgG based Molecules): Distribution by Trial Status
• Figure 14.15 Geographical Clinical Trial Analysis (IgG based Molecules): Distribution by Enrolled Patient Population
• Figure 14.16 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Phase of Development
• Figure 14.17 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Trial Status
• Figure 14.18 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Enrolled Patient Population
• Figure 14.19 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Phase of Development
• Figure 14.20 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Trial Status
• Figure 14.21 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Enrolled Patient Population
• Figure 14.22 Geographical Clinical Trial Analysis (Other Antibody Isotope based Molecules): Distribution by Phase of Development
• Figure 14.23 Geographical Clinical Trial Analysis (Other Antibody Isotope based Molecules): Distribution by Trial Status
• Figure 14.24 Geographical Clinical Trial Analysis (Other Antibody Isotope based Molecules): Distribution by Enrolled Patient Population
• Figure 14.25 Geographical Clinical Trial Analysis: Distribution by Type of Payload
• Figure 14.26 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Phase of Development
• Figure 14.27 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Status
• Figure 14.28 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
• Figure 14.29 Geographical Clinical Trial Analysis (Calicheamicin (Ozogamicin) based Molecules): Distribution by Phase of Development
• Figure 14.30 Geographical Clinical Trial Analysis (Calicheamicin (Ozogamicin) based Molecules): Distribution by Trial Status
• Figure 14.31 Geographical Clinical Trial Analysis (Calicheamicin (Ozogamicin) based Molecules): Distribution by Enrolled Patient Population
• Figure 14.32 Geographical Clinical Trial Analysis (Maytansine based Molecules): Distribution by Phase of Development
• Figure 14.33 Geographical Clinical Trial Analysis (Maytansine based Molecules): Distribution by Trial Status
• Figure 14.34 Geographical Clinical Trial Analysis (Maytansine based Molecules): Distribution by Enrolled Patient Population
• Figure 14.35 Geographical Clinical Trial Analysis (Exatecan based Molecules): Distribution by Phase of Development
• Figure 14.36 Geographical Clinical Trial Analysis (Exatecan based Molecules): Distribution by Trial Status
• Figure 14.37 Geographical Clinical Trial Analysis (Exatecan based Molecules): Distribution by Enrolled Patient Population
• Figure 14.38 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Phase of Development
• Figure 14.39 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Status
• Figure 14.40 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population
• Figure 14.41 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Phase of Development
• Figure 14.42 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Trial Status
• Figure 14.43 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Enrolled Patient Population
• Figure 14.44 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Phase of Development
• Figure 14.45 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Trial Status
• Figure 14.46 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Enrolled Patient Population
• Figure 14.47 Geographical Clinical Trial Analysis: Distribution by Type of Linker
• Figure 14.48 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Phase of Development
• Figure 14.49 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Status
• Figure 14.50 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
• Figure 14.51 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Phase of Development
• Figure 14.52 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Trial Status
• Figure 14.53 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Enrolled Patient Population
• Figure 14.54 Geographical Clinical Trial Analysis (Mc-Val-Cit-PABC based Molecules): Distribution by Phase of Development
• Figure 14.55 Geographical Clinical Trial Analysis (Mc-Val-Cit-PABC based Molecules): Distribution by Trial Status
• Figure 14.56 Geographical Clinical Trial Analysis (Mc-Val-Cit-PABC based Molecules): Distribution by Enrolled Patient Population
• Figure 14.57 Geographical Clinical Trial Analysis (AcBut based Molecules): Distribution by Phase of Development
• Figure 14.58 Geographical Clinical Trial Analysis (AcBut based Molecules): Distribution by Trial Status
• Figure 14.59 Geographical Clinical Trial Analysis (AcBut based Molecules): Distribution by Enrolled Patient Population
• Figure 14.60 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Phase of Development
• Figure 14.61 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Status
• Figure 14.62 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
• Figure 14.63 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Phase of Development
• Figure 14.64 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Status
• Figure 14.65 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
• Figure 14.66 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Phase of Development
• Figure 14.67 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Trial Status
• Figure 14.68 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Enrolled Patient Population
• Figure 16.1 Global Demand for ADC Therapeutics, 2022-2035 (in kg)
• Figure 16.2 Global Demand for ADC Therapeutics: Distribution by Phase of Development, 2022-2035 (in kg)
• Figure 16.3 Global Annual Commercial Demand for ADC Therapeutics, 2022-2035 (in kg)
• Figure 16.4 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Cancer, 2022-2035 (in kg)
• Figure 16.5 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
• Figure 16.6 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2022-2035 (in kg)
• Figure 16.7 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, 2022-2035 (in kg)
• Figure 16.8 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, 2022-2035 (in kg)
• Figure 16.9 Global Commercial Demand for ADC Therapeutics: Distribution by Key Geographical Regions, 2022-2035 (in kg)
• Figure 16.10 Global Annual Clinical Demand for ADC Therapeutics, 2022-2035 (in kg)
• Figure 16.11 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2022-2035 (in kg)
• Figure 16.12 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Cancer, 2022-2035 (in kg)
• Figure 16.13 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
• Figure 16.14 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2022-2035 (in kg)
• Figure 16.15 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2022-2035 (in kg)
• Figure 16.16 Global Clinical Demand for ADC Therapeutics: Distribution by Linker Type, 2022-2035 (in kg)
• Figure 16.17 Global Clinical Demand for ADC Therapeutics: Distribution by Key Geographical Regions, 2022-2035 (in kg)
• Figure 16.18 ADC Therapeutics: Demand and Supply Scenario, 2022-2035
• Figure 17.1 Regional Capability Analysis: ADC Contract Manufacturing in North America
• Figure 17.2 Regional Capability Analysis: ADC Contract Manufacturing in Europe
• Figure 17.3 Regional Capability Analysis: ADC Contract Manufacturing in Asia-Pacific
• Figure 17.4 Regional Capability Analysis: Comparison of Capabilities across Different Regions
• Figure 18.1 AC Matrix: Pictorial Representation
• Figure 18.2 AC Matrix: ADC Contract Manufacturing Scenario in North America
• Figure 18.3 AC Matrix: ADC Contract Manufacturing Scenario in Europe
• Figure 18.4 AC Matrix: ADC Contract Manufacturing Scenario in Asia Pacific
• Figure 19.1 Global ADC Therapeutics Market, 2022-2035 (USD Billion)
• Figure 19.2 ADC Therapeutics Market: Relative Cost of Manufacturing by Type of Component Manufacturing
• Figure 19.3 Global ADC Contract Manufacturing Market, 2022-2035
• Figure 19.4 ADC Contract Manufacturing Market: Distribution by Type of Component Manufacturing, 2022-2035
• Figure 19.5 ADC Contract Manufacturing Market: Distribution by Phase of Development, 2022-2035
• Figure 19.6 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Component Manufacturing, 2022-2035
• Figure 19.7 ADC Contract Manufacturing Market for Commercial Products: Distribution by Antibody Origin, 2022-2035
• Figure 19.8 ADC Contract Manufacturing Market for Commercial Products: Distribution by Antibody Isotype, 2022-2035
• Figure 19.9 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Payload, 2022-2035
• Figure 19.10 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Linker, 2022-2035
• Figure 19.11 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Cancer, 2022-2035
• Figure 19.12 ADC Contract Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035
• Figure 19.13 ADC Contract Manufacturing Market for Commercial Products in North America, 2022-2035
• Figure 19.14 ADC Contract Manufacturing Market for Commercial Products in EU5, 2022-2035
• Figure 19.15 ADC Contract Manufacturing Market for Commercial Products in Rest of the World, 2022-2035
• Figure 19.16 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Component Manufacturing, 2022-2035
• Figure 19.17 ADC Contract Manufacturing Market for Clinical Products: Distribution by Antibody Origin, 2022-2035
• Figure 19.18 ADC Contract Manufacturing Market for Clinical Products: Distribution by Antibody Isotype, 2022-2035
• Figure 19.19 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Payload, 2022-2035
• Figure 19.20 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Linker, 2022-2035
• Figure 19.21 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Cancer, 2022-2035
• Figure 19.22 ADC Contract Manufacturing Market for Clinical Products: Distribution by Key Geographical Regions, 2022-2035
• Figure 19.23 ADC Contract Manufacturing Market for Clinical Products in North America, 2022-2035
• Figure 19.24 ADC Contract Manufacturing Market for Clinical Products in Europe, 2022-2035
• Figure 19.25 ADC Contract Manufacturing Market for Clinical Products in Asia-Pacific, 2022-2035
• Figure 19.26 ADC Contract Manufacturing Market for Clinical Products in MENA, 2022-2035
• Figure 19.27 ADC Contract Manufacturing Market for Clinical Products in Latin America, 2022-2035
• Figure 19.28 ADC Contract Manufacturing Market for Clinical Products in Rest of the World, 2022-2035
• Figure 20.1 SWOT Analysis: Harvey Ball Analysis
• Figure 20.2 Comparison of SWOT Factors: Harvey Ball Analysis
• Figure 21.1 Concluding Remarks: Current Market Landscape of ADC Contract Manufacturing Service Providers
• Figure 21.2 Concluding Remarks: Recent Expansions
• Figure 21.3 Concluding Remarks: Partnerships and Collaborations
• Figure 21.4 Concluding Remarks: Capacity Analysis
• Figure 21.5 Concluding Remarks: Clinical Trial Analysis
• Figure 21.6 Concluding Remarks: Demand Analysis
• Figure 21.7 Concluding Remarks: Market Sizing and Opportunity Analysis